Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
87003 trials found · Page 94 of 4351
-
Can a monthly infusion stop Alzheimer's before it starts?
Disease control OngoingThe primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is …
Phase: PHASE3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC
-
Two drugs vs. one: major trial tests new combo for Tough-to-Treat melanoma
Disease control CompletedThe purpose of the China Extension study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in Chinese participants with no prior systemic t…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New hope for young leukemia patients: massive trial aims to boost survival
Disease control Recruiting nowALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-…
Phase: PHASE3 • Sponsor: Mats Heyman • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
New 'Living Drug' trial targets the immune System's own rogue cells
Disease control Recruiting nowThis study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasi…
Phase: PHASE1 • Sponsor: Huda Salman • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control OngoingPatients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment. The body has different ways of fighting disease and infection, and this research study combines two different ways of fighting canc…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New drug trial aims to stop Cancer's return before it starts
Disease control CompletedThis trial is a randomized, double-blind, multinational Phase III study to evaluate the efficacy and safety of preemptive treatment with FTD/TPI compared with administration of placebo as follow-up, which is the standard of care, in patients who underwent curative resection of co…
Phase: PHASE3 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Apr 09, 2026 19:34 UTC
-
Doctors test Radiation-Chemo combo to help rectal cancer patients avoid surgery
Disease control OngoingThe investigators' data from a phase I study of short course radiation therapy followed by chemotherapy showed 74% complete clinical response (cCR). Given the promising response rate, the investigators are evaluating short course radiation therapy (SCRT) followed by chemotherapy …
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 08, 2026 12:02 UTC
-
New drug combo shows promise for advanced liver cancer in major trial
Disease control OngoingThis is a prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to observe, compare and evaluate the efficacy and safety of Toripalimab combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy …
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
Doctors test Fat-Derived stem cells to help people walk again
Disease control OngoingThe purpose of this research study is to investigate the safety and potential therapeutic effects of autologous, culture-expanded, adipose derived mesenchymal stem cell intrathecal injections in the treatment of spinal cord injury.
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Common disinfectant could supercharge breast cancer radiation therapy
Disease control Recruiting nowThis is a study aimed at testing a commonly available and inexpensive chemical (hydrogen peroxide) for efficacy in sensitising large cancerous lumps in the breast to a standard course of radiotherapy in patients with locally advanced or recurrent breast cancer. Laboratory researc…
Phase: PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
Major trial aims to stop lung Cancer's return after surgery
Disease control Recruiting nowThis phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may h…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Groundbreaking trial tests multiple drugs simultaneously in race to slow ALS
Disease control Recruiting nowThe HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Apr 09, 2026 19:32 UTC
-
Gene therapy offers hope for children with 'Butterfly Skin' disease
Disease control OngoingThe purpose of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa. Funding Source…
Phase: PHASE3 • Sponsor: Castle Creek Biosciences, LLC. • Aim: Disease control
Last updated Apr 13, 2026 20:16 UTC
-
New pill takes on chemo in hard-to-treat lung cancer
Disease control OngoingA Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC
-
Engineered immune cells take on deadly childhood brain cancer
Disease control Recruiting nowThe primary purpose of this study is to test whether CAR T cells targeting GD2 (GD2CART) can be successfully made and safely given to children and adults with H3K27M-mutant diffuse midline glioma (DMG). Eligible subjects may have DMG arising in the pons (called difuse intrinisic …
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Engineered immune cells take on relapsed leukemia in new trial
Disease control OngoingThis is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (ALL).
Phase: PHASE1, PHASE2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC
-
New drug combo tested to stop lung cancer return after surgery
Disease control OngoingThe primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant …
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New hope for ALS: major trial tests drug to slow devastating disease
Disease control OngoingA Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Phase: PHASE2, PHASE3 • Sponsor: MediciNova • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC
-
New drug cocktail shows promise in halting incurable liver cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 24, 2026 16:17 UTC
-
Ready-Made immune cell therapy tested for Tough-to-Treat blood cancers
Disease control OngoingThis is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lym…
Phase: PHASE1, PHASE2 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC